Key points from article :
MyMD Pharmaceuticals' lead compound, MYMD-1 to treat autoimmune and age-related diseases, including extending human lifespan.
Starting a Phase 2 human trial in January 2022, targeting sarcopenia as its primary endpoint.
“We have 14 patents issued for MyMD-1,” - Adam Kaplin, CSO at MyMD.
Focus on “markers like muscle loss, weakness, frailty, and increased predisposition for age-related pathology.”
It reduces chronic inflammation through inhibition of several cytokines, including TNF alpha.
“It’s the first proinflammatory cytokine to go up when you get an infection/inflammatory illness, and it turns on IL-6 and IL-1.”
It is also selective and able to cross the blood brain barrier.
“..to shut down the inflammation and measure sarcopenia over time in at-risk population,” - Kaplin.
Followed by a 6-month trial in people with increased signs of inflammation.
Efficacy data is expected by the end of the first quarter of 2022.
